0001027838false00010278382024-08-052024-08-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 5, 2024

TACTILE SYSTEMS TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-37799

 

41-1801204

(State or other jurisdiction of

 

(Commission

 

(I.R.S. Employer

incorporation)

 

File Number)

 

Identification No.)

3701 Wayzata Blvd, Suite 300, Minneapolis, MN 55416

(Address of principal executive offices) (Zip Code)

(612) 355-5100

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $0.001 Per Share

TCMD

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On August 5, 2024, Tactile Systems Technology, Inc. (“we,” “us,” and “our”) issued a press release disclosing our results of operations and financial condition for our most recently completed fiscal quarter. A copy of the press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in that filing.

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

EXHIBIT INDEX

Exhibit
No.

 

Description

 

 

 

99.1

 

Press Release dated August 5, 2024 (Earnings Release)

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TACTILE SYSTEMS TECHNOLOGY, INC.

Date: August 5, 2024

By:

/s/ Elaine M. Birkemeyer

Elaine M. Birkemeyer

Chief Financial Officer

Exhibit 99.1

Tactile Systems Technology, Inc. Reports Second Quarter 2024 Financial Results

MINNEAPOLIS, MN, August 5, 2024 Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2024.

Second Quarter 2024 Highlights:

Total revenue increased 7% year-over-year to $73.2 million

Lymphedema product revenue increased 8% year-over-year

Airway clearance product revenue increased 2% year-over-year

Net income of $4.3 million versus a net loss of $0.1 million in Q2 2023
Adjusted EBITDA of $9.1 million versus $6.1 million in Q2 2023
Operating cashflow of $13.1 million, ended Q2 2024 with $73.6 million in cash and cash equivalents
510(k) clearance for Nimbl system, our next generation lymphedema therapy platform
Appointed Sheri Dodd as President and CEO, effective July 1, 2024

“We are pleased with our second quarter performance, delivering total revenue growth of 7% year-over-year and significant improvements in profitability, reflected in a 49% year-over-year increase in adjusted EBITDA,” said Sheri Dodd, President and Chief Executive Officer of Tactile Medical. “We also continued to strengthen our balance sheet, generating $13 million of operating cashflow in the quarter.”

Ms. Dodd continued, “My first few weeks as CEO of Tactile Medical have validated my confidence in the immense opportunity to transform care for patients with lymphedema and airway clearance disorders. As these markets continue to grow, patient populations remain chronically underdiagnosed, undertreated, and underserved. Looking ahead, we will continue investing in our products, patient services, and sales and order operations to provide increasingly innovative solutions, enable simplicity and scale, and ultimately widen market access. I believe we are well positioned to tangibly improve patient care while driving sustainable and profitable growth in 2024 and beyond.”

Second Quarter 2024 Financial Results

Total revenue in the second quarter of 2024 increased $4.9 million, or 7%, to $73.2 million, compared to $68.3 million in the second quarter of 2023. The increase in total revenue was attributable to an increase of $4.7 million, or 8%, in sales and rentals of the lymphedema product line and an increase of $0.2 million, or 2%, in sales of the airway clearance product line in the quarter ended June 30, 2024, compared to the second quarter of 2023.

Gross profit in the second quarter of 2024 increased $5.8 million, or 12%, to $54.1 million, compared to $48.3 million in the second quarter of 2023. Gross margin was 73.9% of revenue, compared to 70.7% of revenue in the second quarter of 2023. Non-GAAP gross margin was 74.3% of revenue, compared to 71.1% of revenue in the second quarter of 2023.


Operating expenses in the second quarter of 2024 increased $2.0 million, or 4%, to $48.3 million, compared to $46.2 million in the second quarter of 2023.

Operating income was $5.8 million in the second quarter of 2024, compared to $2.1 million in the second quarter of 2023. Non-GAAP operating income in the second quarter of 2024 was $6.5 million, compared to $3.6 million in the second quarter of 2023.

Other income was $0.2 million in the second quarter of 2024, compared to other expense of $0.8 million in the second quarter of 2023.

Income tax expense was $1.8 million in the second quarter of 2024, compared to $1.3 million in the second quarter of 2023.

Net income in the second quarter of 2024 was $4.3 million, or $0.18 per diluted share, compared to a net loss of $0.1 million, or ($0.00) per diluted share, in the second quarter of 2023. Non-GAAP net income in the second quarter of 2024 was $4.8 million, compared to $1.0 million in the second quarter of 2023.

Weighted average shares used to compute diluted net income (loss) per share were 24.1 million and 23.4 million for the second quarters of 2024 and 2023, respectively.

Adjusted EBITDA was $9.1 million in the second quarter of 2024, compared to $6.1 million in the second quarter of 2023.

First Six Months 2024 Financial Results

Total revenue for the six months ended June 30, 2024, increased $7.1 million, or 6%, to $134.3 million, compared to $127.2 million for the six months ended June 30, 2023. The increase in total revenue was attributable to an increase of $7.2 million, or 7%, in sales and rentals of the lymphedema product line, slightly offset by a decrease of $0.1 million, or 1%, in sales of the airway clearance product line for the six months ended June 30, 2024, compared to the six months ended June 30, 2023.

Net income for the six months ended June 30, 2024, was $2.1 million, or $0.09 per diluted share, compared to a net loss of $2.0 million, or ($0.09) per diluted share, for the six months ended June 30, 2023. Non-GAAP net income for the six months ended June 30, 2024, was $3.5 million, compared to $0.4 million for the six months ended June 30, 2023.

Weighted average shares used to compute diluted net income (loss) per share were 24.1 million and 22.3 million for the six months ended June 30, 2024 and 2023, respectively.

Adjusted EBITDA was $10.1 million in the six months ended June 30, 2024, compared to $6.6 million in the six months ended June 30, 2023.

Balance Sheet Summary

As of June 30, 2024, the Company had $73.6 million in cash and cash equivalents and $27.8 million of outstanding borrowings under its credit agreement, compared to $61.0 million in cash and cash


equivalents and $29.3 million of outstanding borrowings under its credit agreement as of December 31, 2023.

2024 Financial Outlook

The Company is updating its 2024 financial outlook and now expects full year 2024 total revenue in the range of $293 million to $298 million, representing growth of approximately 7% to 9% year-over-year, compared to total revenue of $274.4 million in 2023. The Company’s prior 2024 guidance expectation was total revenue in the range of $300 million to $305 million, representing growth of approximately 9% to 11%.

Conference Call

Management will host a conference call with a question-and-answer session at 5:00 p.m. Eastern Time on August 5, 2024, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13745955. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13745955. The webcast will be archived at investors.tactilemedical.com.

About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the Company’s ability to obtain reimbursement from third-party payers for its products; the impacts of inflation, rising interest rates or a recession; the adequacy of the Company’s liquidity to pursue its business objectives; adverse economic conditions or intense competition; price increases for supplies and components; wage and component price inflation; loss of a key supplier; entry of new competitors and products; compliance with and changes in federal, state and local government regulation; loss or retirement of key executives, including transition matters related to the Company’s recent Chief Executive Officer change; technological obsolescence


of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

This press release includes the non-GAAP financial measures of Adjusted EBITDA, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income (loss), and non-GAAP net income (loss), which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”).

Adjusted EBITDA in this release represents net income or loss, plus interest expense, net, or less interest income, net, less income tax benefit or plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense, plus or minus the change in fair value of earn-out and plus executive transition costs. Non-GAAP gross profit in this release represents gross profit plus non-cash intangible amortization expense. Non-GAAP gross margin in this release represents non-GAAP gross profit divided by revenue. Non-GAAP operating income (loss) in this release represents operating income (loss) adjusted for non-cash intangible amortization expense, change in fair value of earn-out and executive transition expenses. Non-GAAP net income (loss) represents net income (loss) adjusted for non-cash intangible amortization expense, change in fair value of earn-out and executive transition expenses, and adjusted for the income tax effect on reconciling items. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP measures are included in this press release.

These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these measures principally as measures of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating plan and financial projections. The Company believes these measures are useful to investors as supplemental information and because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company also believes these non-GAAP financial measures are useful to its management and investors as a measure of comparative operating performance from period to period. In addition, Adjusted EBITDA is used as a performance metric in the Company’s compensation program.

The non-GAAP financial measures presented in this release should not be considered as an alternative to, or superior to, their respective GAAP financial measures, as measures of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and they should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it


does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating non-GAAP financial measures, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP financial measures should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using non-GAAP financial measures on a supplemental basis. The Company’s definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.


Tactile Systems Technology, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

    

June 30,

    

December 31,

(In thousands, except share and per share data)

    

2024

    

2023

Assets

Current assets

Cash and cash equivalents

$

73,618

$

61,033

Accounts receivable

 

41,935

 

43,173

Net investment in leases

 

13,551

 

14,195

Inventories

 

18,846

 

22,527

Prepaid expenses and other current assets

 

3,909

 

4,366

Total current assets

 

151,859

 

145,294

Non-current assets

Property and equipment, net

 

5,691

 

6,195

Right of use operating lease assets

 

17,828

 

19,128

Intangible assets, net

 

44,883

 

46,724

Goodwill

31,063

31,063

Accounts receivable, non-current

 

4,511

 

10,936

Deferred income taxes

 

19,408

 

19,378

Other non-current assets

 

3,541

 

2,720

Total non-current assets

 

126,925

 

136,144

Total assets

$

278,784

$

281,438

Liabilities and Stockholders' Equity

Current liabilities

Accounts payable

$

5,094

$

6,659

Note payable

2,956

2,956

Accrued payroll and related taxes

 

12,090

 

16,789

Accrued expenses

 

6,702

 

5,904

Income taxes payable

 

496

 

1,467

Operating lease liabilities

 

2,799

 

2,807

Other current liabilities

 

4,075

 

4,475

Total current liabilities

 

34,212

 

41,057

Non-current liabilities

Note payable, non-current

24,698

26,176

Accrued warranty reserve, non-current

 

1,561

 

1,681

Income taxes payable, non-current

 

495

 

446

Operating lease liabilities, non-current

17,142

 

18,436

Total non-current liabilities

 

43,896

 

46,739

Total liabilities

 

78,108

 

87,796

Stockholders’ equity:

Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of June 30, 2024 and December 31, 2023

 

 

Common stock, $0.001 par value, 300,000,000 shares authorized; 23,966,748 shares issued and outstanding as of June 30, 2024; 23,600,584 shares issued and outstanding as of December 31, 2023

 

24

 

24

Additional paid-in capital

 

179,669

 

174,724

Retained earnings

 

20,983

 

18,894

Total stockholders’ equity

 

200,676

 

193,642

Total liabilities and stockholders’ equity

$

278,784

$

281,438


Tactile Systems Technology, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

Three Months Ended

Six Months Ended

June 30,

June 30,

(In thousands, except share and per share data)

    

2024

    

2023

    

2024

    

2023

    

Revenue

Sales revenue

$

64,267

$

59,802

$

117,574

$

112,593

Rental revenue

 

8,951

 

8,537

 

16,732

 

14,592

Total revenue

 

73,218

 

68,339

 

134,306

 

127,185

Cost of revenue

Cost of sales revenue

 

16,263

 

16,865

 

31,207

 

31,507

Cost of rental revenue

 

2,852

 

3,175

 

5,567

 

5,911

Total cost of revenue

 

19,115

 

20,040

 

36,774

 

37,418

Gross profit

Gross profit - sales revenue

 

48,004

 

42,937

 

86,367

 

81,086

Gross profit - rental revenue

 

6,099

 

5,362

 

11,165

 

8,681

Gross profit

 

54,103

 

48,299

 

97,532

 

89,767

Operating expenses

Sales and marketing

 

28,608

 

28,206

 

55,965

 

54,508

Research and development

 

2,234

 

1,833

 

4,377

 

4,066

Reimbursement, general and administrative

 

16,779

 

14,991

 

33,040

 

30,425

Intangible asset amortization and earn-out

633

1,211

1,265

2,516

Total operating expenses

 

48,254

 

46,241

 

94,647

 

91,515

Income (loss) from operations

 

5,849

 

2,058

 

2,885

 

(1,748)

Other income (expense)

 

225

 

(838)

 

380

 

(1,831)

Income (loss) before income taxes

 

6,074

 

1,220

 

3,265

 

(3,579)

Income tax expense (benefit)

 

1,776

 

1,320

 

1,176

 

(1,593)

Net income (loss)

$

4,298

$

(100)

$

2,089

$

(1,986)

Net income (loss) per common share

Basic

$

0.18

$

0.00

$

0.09

$

(0.09)

Diluted

$

0.18

$

0.00

$

0.09

$

(0.09)

Weighted-average common shares used to compute net income (loss) per common share

Basic

23,873,379

23,352,530

23,769,604

22,323,856

Diluted

24,099,047

23,352,530

24,073,986

22,323,856


Tactile Systems Technology, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

Six Months Ended June 30, 

(In thousands)

    

2024

    

2023

Cash flows from operating activities

Net income (loss)

$

2,089

$

(1,986)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

Depreciation and amortization

3,345

3,269

Deferred income taxes

(30)

Stock-based compensation expense

3,899

3,831

Loss on disposal of property and equipment and intangibles

54

3

Change in fair value of earn-out liability

1,230

Changes in assets and liabilities, net of acquisition:

Accounts receivable

1,238

8,273

Net investment in leases

644

2,911

Inventories

3,681

2,809

Income taxes

(922)

(3,967)

Prepaid expenses and other assets

(364)

(697)

Right of use operating lease assets

(2)

50

Accounts receivable, non-current

6,425

7,631

Accounts payable

(1,592)

(696)

Accrued payroll and related taxes

(4,699)

(3,300)

Accrued expenses and other liabilities

300

(5,954)

Net cash provided by operating activities

14,066

13,407

Cash flows from investing activities

Purchases of property and equipment

(982)

(1,043)

Proceeds from sale of property and equipment

12

Intangible assets expenditures

(57)

(99)

Net cash used in investing activities

(1,027)

(1,142)

Cash flows from financing activities

Payments on earn-out

(5,000)

Payments on note payable

(1,500)

(1,500)

Proceeds from exercise of common stock options

2

11

Proceeds from the issuance of common stock from the employee stock purchase plan

1,044

882

Proceeds from issuance of common stock at market

34,625

Net cash (used in) provided by financing activities

(454)

29,018

Net increase in cash and cash equivalents

12,585

41,283

Cash and cash equivalents – beginning of period

61,033

21,929

Cash and cash equivalents – end of period

$

73,618

$

63,212

Supplemental cash flow disclosure

Cash paid for interest

$

1,099

$

1,925

Cash paid for taxes

$

2,177

$

2,415

Capital expenditures incurred but not yet paid

$

27

$

8


The following table summarizes revenue by product line for the three and six months ended June 30, 2024 and 2023:

Three Months Ended

Six Months Ended

June 30,

June 30,

(In thousands)

    

2024

2023

2024

2023

Revenue

Lymphedema products

$

64,683

$

59,999

$

116,996

$

109,751

Airway clearance products

8,535

8,340

17,310

17,434

Total

$

73,218

$

68,339

$

134,306

$

127,185

Percentage of total revenue

Lymphedema products

 

88%

 

88%

 

87%

 

86%

Airway clearance products

12%

12%

13%

14%

Total

 

100%

 

100%

 

100%

 

100%

The following table contains a reconciliation of GAAP gross profit and margin to non-GAAP gross profit and margin:

Tactile Systems Technology, Inc.

Reconciliation of Gross Profit and Margin to Non-GAAP Gross Profit and Margin

(Unaudited)

Three Months Ended

Six Months Ended

June 30,

June 30,

(Dollars in thousands)

    

2024

    

2023

    

2024

    

2023

Gross profit, as reported

 

$

54,103

$

48,299

$

97,532

$

89,767

Gross margin, as reported

73.9

%

70.7

%

72.6

%

70.6

%

Reconciling items:

Non-cash intangible amortization expense

$

317

$

315

$

633

$

629

Non-GAAP gross profit

$

54,420

$

48,614

$

98,165

$

90,396

Non-GAAP gross margin

74.3

%

71.1

%

73.1

%

71.1

%


The following table contains a reconciliation of GAAP operating income (loss) to non-GAAP operating income:

Tactile Systems Technology, Inc.

Reconciliation of GAAP Operating Income (Loss) to Non-GAAP Operating Income

(Unaudited)

Three Months Ended

Six Months Ended

June 30,

June 30,

(Dollars in thousands)

    

2024

    

2023

    

2024

    

2023

GAAP operating income (loss)

 

$

5,849

$

2,058

$

2,885

$

(1,748)

Reconciling items:

Non-cash intangible amortization expense impacting gross profit

$

317

$

315

$

633

$

629

Non-cash intangible amortization expense impacting operating expenses

632

641

1,265

1,286

Change in fair value of earn-out

570

1,230

Executive transition expenses

(340)

(25)

Non-GAAP operating income:

$

6,458

$

3,584

$

4,758

$

1,397

The following table contains a reconciliation of GAAP net income (loss) to non-GAAP net income:

Tactile Systems Technology, Inc.

Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Income

(Unaudited)

Three Months Ended

Six Months Ended

June 30,

June 30,

(Dollars in thousands)

    

2024

    

2023

    

2024

    

2023

GAAP net income (loss)

$

4,298

$

(100)

$

2,089

$

(1,986)

Reconciling items:

Non-cash intangible amortization expense impacting gross profit

$

317

$

315

$

633

$

629

Non-cash intangible amortization expense impacting operating expenses

632

641

1,265

1,286

Change in fair value of earn-out

570

1,230

Executive transition expenses

(340)

(25)

Income tax expense on reconciling items*

(152)

(382)

(468)

(786)

Non-GAAP net income

$

4,755

$

1,044

$

3,494

$

373

* The effect of income tax on the reconciling items is estimated using the Company's effective statutory tax rate.


The following table contains a reconciliation of net income (loss) to Adjusted EBITDA for the three and six months ended June 30, 2024 and 2023, as well as the dollar and percentage change between the comparable periods:

Tactile Systems Technology, Inc.

Reconciliation of Net Income (Loss) to Non-GAAP Adjusted EBITDA

(Unaudited)

Three Months Ended

Increase

Six Months Ended

Increase

June 30,

(Decrease)

June 30,

(Decrease)

(Dollars in thousands)

    

2024

    

2023

    

$

    

%

    

2024

    

2023

$

    

%

Net income (loss)

 

$

4,298

$

(100)

$

4,398

 

N.M.

%

$

2,089

$

(1,986)

$

4,075

 

205

%

Interest (income) expense, net

(225)

838

(1,063)

 

(127)

%

(371)

1,831

(2,202)

 

(120)

%

Income tax expense (benefit)

1,776

1,320

456

 

35

%

1,176

(1,593)

2,769

 

(174)

Depreciation and amortization

1,711

1,640

71

 

4

%

3,345

3,269

76

 

2

%

Stock-based compensation

1,860

1,808

52

 

3

%

3,899

3,831

68

 

2

%

Change in fair value of earn-out

570

(570)

(100)

%

1,230

(1,230)

(100)

%

Executive transition costs

(340)

(340)

%

(25)

(25)

%

Adjusted EBITDA

$

9,080

$

6,076

$

3,004

 

49

%

$

10,113

$

6,582

$

3,531

 

54

%

Investor Inquiries:

Sam Bentzinger

Gilmartin Group

[email protected]